{{ $DoctorName }} @if (isset(session()->get('doctor')['vCentralCode'])) {{ session()->get('doctor')['vCentralCode'] }} @endif
@if (isset(session()->get('doctor')['vCentralCode']))
Logout
@endif

{{ $ActivityTypeName }}

{{ $ActivityName }}

@csrf
@if (isset(session()->get('doctor')['vCentralCode']))
Back
@else
@endif

1.0 METOPROLOL – Molecular Aspects

  1. In the treatment of cardiovascular diseases, which is the most commonly prescribed Beta blocker by you? *

  2. Which indication do you most prescribe Metoprolol? *

  3. Which age group of patients will receive Metoprolol the most in your clinical practice? *

  4. Which drug do you prefer to give in combination with Metoprolol in CVD? *

  5. How do you find the tolerability of Metoprolol? *

  6. Which age group of patients require frequent dosage adjustment for Metoprolol in your clinical practice? *

  7. Do you see an improved survival in your Heart failure patients with Metoprolol? *

  8. Do you attribute Sympathetic Overdrive as a cause of essential hypertension in young individuals? *

  9. Do you perceive benefits of the Extended-Release formulation of Metoprolol to your patients? *

2.0 PROLOMET (Extended-Release Metoprolol Succinate 12.5/25/50/100 mg) Communication Aspects

  1. How do you find the visual communication depicted for PROLOMET? *

  2. Is the clinical information adequate and updated on the marketing aids? *

  3. Do you see the benefits of consistent release of Metoprolol from Prolomet XL in your clinical practice in terms of reduction in heart rate for 24 hours? *

  4. Do you get the predictable response with dosage titration of Prolomet XL in your clinical practice? *

  5. In MERIT-HF trial, Metoprolol improved survival in various patients with HF like Elderly, Diabetes Patients, Patients with CKD, Women with HF, and HF patients with COPD. Do you relate this outcome in your clinical practice? *

  6. Does the ‘Smallest pill’ of PROLOMET – R confer any advantage to your patients? *